Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 11/20 | 0.74 |
| ▸ | RIPK3 | Q9Y572 | 7/20 | 0.66 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1745961 | 0.95 | CSNK1E (0.76) | CSNK1ERIPK3HASPIN | |
| SCHEMBL3116569 | 0.89 | CSNK1E (0.74) | CSNK1ERIPK3CSNK1D | |
| SCHEMBL3113280 | 0.89 | CSNK1E (0.67) | CSNK1ERIPK3CSNK1DHASPIN | |
| SCHEMBL21100909 | 0.86 | RIPK3 (0.86) | CSNK1ERIPK3CSNK1DMAPK14HASPIN | |
| SCHEMBL3116055 | 0.85 | CSNK1E (0.75) | CSNK1ERIPK3HASPIN | |
| SCHEMBL3124139 | 0.85 | CSNK1E (0.65) | CSNK1ERIPK3HASPIN | |
| SCHEMBL3116479 | 0.85 | CSNK1E (0.74) | CSNK1ERIPK3HASPIN | |
| SCHEMBL23515899 | 0.85 | CSNK1E (0.74) | CSNK1ERIPK3HASPIN | |
| SCHEMBL3115670 | 0.85 | CSNK1E (1.00) | CSNK1ERIPK3HASPIN | |
| SCHEMBL3122182 | 0.85 | CSNK1E (1.00) | CSNK1ERIPK3HASPIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170889-B1 | 6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2016-08-17 | — | — | EP | claimed |
| US-8846676-B2 | 6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-09-30 | — | — | US | claimed |
| US-8354405-B2 | 6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-15 | — | — | US | claimed |
| US-20130012516-A1 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-01-10 | — | — | US | claimed |
| US-20100179154-A1 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-15 | — | — | US | claimed |
| US-20210177847-A1 | Compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2021-06-17 | — | — | US | disclosed |
| US-10973820-B2 | Compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2021-04-13 | — | — | US | disclosed |
| WO-2020249717-A1 | CASEIN KINASE 1 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION SUCH AS MUSCULAR DYSTROPHY AND CANCER | Facio Intellectual Property B.V. (NL) | 2020-12-17 | — | — | WO | disclosed |
| WO-2019115711-A1 | COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2019-06-20 | — | — | WO | disclosed |
| EP-3498278-A1 | COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2019-06-19 | — | — | EP | disclosed |
| US-20190175596-A1 | Compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2019-06-13 | — | — | US | disclosed |
| EP-2170889-B1 | 6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2016-08-17 | — | — | EP | disclosed |
| US-8846676-B2 | 6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8354405-B2 | 6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-15 | — | — | US | disclosed |
| US-20130012516-A1 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-01-10 | — | — | US | disclosed |
| US-20100179154-A1 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175596-A1 | Compounds for treatment of diseases related to DUX4 expression | ZFX, MTPN, UTRN | CSNK1E 2897/4885RIPK3 3485/4885CSNK1D 2691/4885 |
| US-20210177847-A1 | Compounds for treatment of diseases related to DUX4 expression | SMN1; SMN2, UTRN, DDX21 | CSNK1E 2990/4885RIPK3 3657/4885CSNK1D 3706/4885 |
| US-10973820-B2 | Compounds for treatment of diseases related to DUX4 expression | ZFX, MTPN, UTRN | CSNK1E 2897/4885RIPK3 3485/4885CSNK1D 2691/4885 |
| US-20130012516-A1 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CBR3, DHFR, IL4I1 | CSNK1E 555/4885RIPK3 3076/4885CSNK1D 507/4885 |
| US-20100179154-A1 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CBR3, DHFR, IL4I1 | CSNK1E 555/4885RIPK3 3076/4885CSNK1D 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.